List of Excipients in Branded Drug RUGBY HEARTBURN TREATMENT

« Back to Dashboard

Generic Drugs Containing RUGBY HEARTBURN TREATMENT

Company	Ingredient	NDC	Excipient
Rugby Laboratories	lansoprazole	0536-1034	D&C RED NO. 28
Rugby Laboratories	lansoprazole	0536-1034	D&C YELLOW NO. 10
Rugby Laboratories	lansoprazole	0536-1034	FD&C BLUE NO. 1
Rugby Laboratories	lansoprazole	0536-1034	GELATIN

What are the Most Frequently-Used Excipients in RUGBY HEARTBURN TREATMENT?

# Of NDCs	Excipient
1	D&C RED NO. 28
1	D&C YELLOW NO. 10
1	FD&C BLUE NO. 1
1	GELATIN

Rugby Heartburn Treatment Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Rugby Heartburn Treatment is an OTC famotidine product positioned against branded Pepcid AC and other private-label acid reducers. Its commercial opportunity is driven less by composition-of-matter patents and more by cost-efficient excipient systems, tablet performance, packaging, retailer supply, and differentiated dosage forms. The strongest opportunities are chewable, orally disintegrating, pediatric-directed, combination, and clean-label variants that remain within the applicable FDA OTC framework.

What is Rugby Heartburn Treatment?

Rugby Heartburn Treatment is a private-label OTC heartburn medicine whose active ingredient is generally famotidine, an H2-receptor antagonist. Rugby-branded products have been marketed in common 10 mg and 20 mg strengths, typically as film-coated tablets or comparable immediate-release solid oral forms.

Attribute	Product position
Brand	Rugby Heartburn Treatment
Active ingredient	Famotidine
Typical strengths	10 mg and 20 mg
Drug category	OTC H2-receptor antagonist
Primary indication	Relief and prevention of heartburn
Reference-brand comparison	Pepcid AC
Dosage form	Immediate-release oral tablet; exact SKU may vary
Commercial model	Private-label pharmacy and retail distribution
Primary buyers	Pharmacies, hospitals, wholesalers, mass retailers and institutional purchasers
Main competitive factors	Unit cost, supply reliability, tablet quality, packaging and retailer margin

Product-specific inactive ingredients can vary by strength, manufacturer, market, and NDC. A commercial excipient assessment must therefore distinguish the exact Rugby SKU from the broader Rugby brand family.

What excipient systems are likely used in Rugby Heartburn Treatment?

The likely formulation platform is a conventional immediate-release tablet using standard direct-compression or wet-granulation excipients. Typical functional categories include:

Excipient function	Common candidate materials	Commercial purpose
Diluent	Microcrystalline cellulose, lactose, dibasic calcium phosphate, mannitol	Tablet mass, compressibility and dose uniformity
Binder	Pregelatinized starch, povidone, hydroxypropyl cellulose	Mechanical strength and low friability
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Rapid tablet breakup
Glidant	Colloidal silicon dioxide	Powder flow and weight control
Lubricant	Magnesium stearate, sodium stearyl fumarate	Ejection and tooling protection
Surfactant or wetting aid	Sodium lauryl sulfate or equivalent	Wetting and dissolution support
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Appearance, handling and swallowability
Sweetener and flavor	Sucralose, aspartame, saccharin, mint or fruit flavor	Chewable or orally disintegrating formats
Colorant	Approved lake or oxide pigments	Product identification and retail differentiation

The formulation objective is not maximum excipient complexity. It is reliable disintegration, acceptable hardness, low friability, stable dissolution and low cost at high manufacturing volumes.

Which excipients are most important for famotidine tablets?

Famotidine has a relatively low dose compared with the total tablet weight, so content uniformity and blend segregation are important. Microcrystalline cellulose, pregelatinized starch, or a comparable carrier can support uniform distribution of the active ingredient.

Disintegration is commercially important because consumers expect rapid heartburn relief. Crospovidone and croscarmellose sodium are common choices. Excessive lubricant concentration or over-lubrication can slow wetting and dissolution, particularly in direct-compression systems.

Film coating can improve swallowability and reduce tablet dust. It also creates an opportunity for color and package differentiation without changing the active ingredient. Coating weight must remain controlled because a heavy or hydrophobic coating can delay disintegration.

How can Rugby improve its excipient strategy?

The most valuable strategy is a platform approach using a small number of validated excipient systems across 10 mg and 20 mg strengths. This can reduce raw-material complexity, simplify supplier qualification and support manufacturing at multiple contract sites.

Recommended formulation priorities

1. Rapid immediate-release performance
   Optimize disintegrant level, lubricant concentration, tablet porosity and compression force to produce fast breakup without compromising mechanical strength.

2. Low-cost direct compression
   Use directly compressible grades of microcrystalline cellulose, mannitol or dibasic calcium phosphate where they provide acceptable flow and content uniformity.

3. Low-dose blend control
   Evaluate ordered mixing, carrier particle-size distribution and segregation during transfer and hopper discharge.

4. Robust coating process
   Use a thin, aqueous film coat that improves handling and swallowability without materially increasing cycle time.

5. Supplier redundancy
   Qualify at least two sources for high-impact excipients such as microcrystalline cellulose, crospovidone, magnesium stearate and coating polymers.

6. Packaging compatibility
   Test moisture uptake, tablet hardness, dissolution and appearance in bottles, unit-dose blisters and high-barrier blister systems.

What formulation opportunities exist beyond the standard tablet?

The strongest commercial opportunities involve dosage forms that address convenience, swallowing difficulty and speed of use.

Chewable famotidine

A chewable tablet could expand use among consumers who do not want to swallow a conventional tablet. Mannitol, sorbitol, xylitol, crospovidone, flavor and high-intensity sweeteners are likely formulation tools.

Key development risks include:

• Famotidine bitterness
• Hygroscopicity from polyols
• Flavor loss during shelf life
• Tablet capping or friability
• Sugar-free labeling requirements
• Consumer acceptance of aftertaste

A taste-masked chewable product could command a higher retail price than a standard private-label tablet while preserving the same active ingredient and OTC indication.

Orally disintegrating tablet

An orally disintegrating tablet could target consumers seeking water-free administration. The formulation would require rapid wetting, porous structure, low friability and effective taste masking. Mannitol, crospovidone, low-substituted hydroxypropyl cellulose and coated or complexed famotidine particles are potential tools.

The main tradeoff is manufacturing cost. Orally disintegrating tablets often require specialized compression, packaging or moisture protection.

Effervescent or powder format

A sachet or effervescent tablet could provide a differentiated format, but the formulation is more technically demanding. Acid-base systems can affect famotidine stability, moisture sensitivity and dissolution behavior. Aluminum or high-barrier foil packaging may be required.

This format is more suitable for a premium private-label line than for the lowest-cost Rugby SKU.

Liquid or suspension

A liquid product could serve consumers with swallowing difficulty, but famotidine suspension development raises issues involving taste, pH, preservative efficacy, sedimentation, viscosity and multi-dose dosing accuracy. The format also increases packaging, shipping and stability costs.

A liquid is more commercially attractive where institutional, pediatric or specialty-pharmacy demand justifies the added complexity.

What formulation patents protect Rugby Heartburn Treatment?

The standard famotidine tablet is unlikely to have meaningful composition-of-matter patent protection because famotidine is an established active pharmaceutical ingredient. The principal commercial barriers are regulatory compliance, manufacturing know-how, supplier qualification, brand placement and retailer contracts.

Protection category	Relevance to Rugby Heartburn Treatment
Famotidine composition patent	Generally not a current barrier for ordinary OTC commercialization
Standard tablet excipient combination	Usually weak unless tied to a novel, non-obvious performance result
Taste-masking system	Potentially protectable if technically distinctive
Orally disintegrating formulation	Potential patent value if it solves stability, taste or friability problems
Extended-release system	Potentially protectable but less aligned with standard heartburn positioning
Packaging configuration	Possible design or utility protection
Manufacturing process	Potential trade-secret and process-control value
Method-of-use claims	Limited value where the use is already established in OTC labeling
Brand and trade dress	Important commercial assets, separate from formulation patents

A private-label product typically relies on a regulatory pathway and supply agreement rather than an extensive proprietary patent estate. Any patent analysis should review the exact formulation owner, manufacturer, NDA or ANDA status, and relevant U.S. and international filings.

What is the FDA regulatory status of Rugby Heartburn Treatment?

Famotidine is an established OTC heartburn active ingredient under the FDA’s nonprescription drug framework. A commercial product must conform to the applicable monograph conditions or hold an appropriate FDA approval, depending on the product’s formulation, labeling, dosage form and regulatory pathway.

The regulatory review should cover:

• Active ingredient identity and strength
• Permitted OTC indication
• Age restrictions
• Directions and maximum daily use
• Warning statements
• Inactive ingredient acceptability
• Dissolution and performance testing
• Stability data
• Manufacturing under current good manufacturing practice
• Package and label compliance

A novel dosage form may not fit cleanly within the same regulatory pathway as a conventional tablet. Taste-masked, chewable, orally disintegrating, liquid or combination products may require a more detailed regulatory assessment.

What is the Orange Book status of Rugby Heartburn Treatment?

The Orange Book is most relevant to approved prescription drugs and certain approved nonprescription products. A private-label OTC famotidine product does not automatically have an Orange Book patent estate comparable to a branded prescription product.

For commercial diligence, the relevant questions are:

• Whether the exact product is listed by FDA as an approved drug product
• Whether it is marketed under an NDA, ANDA or OTC monograph pathway
• Whether any patents are listed for the exact product
• Whether an approved labeling carve-out is needed
• Whether a competing applicant could file a Paragraph IV certification

A standard OTC monograph-compliant famotidine product generally presents a lower Paragraph IV risk profile than a prescription product protected by listed formulation or method-of-use patents. Paragraph IV exposure becomes more relevant if a particular Rugby product is tied to an approved application with listed patents.

When does Rugby Heartburn Treatment lose exclusivity?

The product’s active ingredient is already generic and widely available. Rugby does not have the type of exclusivity timeline associated with a newly approved prescription medicine.

Exclusivity type	Expected relevance
New chemical entity exclusivity	Not applicable to established famotidine
Prescription orphan exclusivity	Not applicable to standard OTC heartburn use
New pediatric exclusivity	Product-specific and not expected to define the ordinary OTC market
NDA market exclusivity	Depends on the exact approved application
Patent exclusivity	Depends on product-specific formulation or use patents
Retail private-label exclusivity	Contractual rather than statutory
Brand exclusivity	Trademark and retailer positioning rather than active-ingredient protection

The key commercial event is therefore not patent expiration. It is the retailer’s decision to maintain or replace the supplier based on price, service levels, quality performance and supply continuity.

Which companies challenge Rugby Heartburn Treatment?

The product competes primarily with other private-label famotidine suppliers and branded acid-reducer companies. Relevant competitors include:

• Pepcid and Pepcid AC
• Store-brand famotidine products from major pharmacy chains
• Perrigo-supplied private-label products
• Major Pharmaceuticals and related OTC suppliers
• Dr. Reddy’s Laboratories and other generic manufacturers
• Retailer-controlled OTC sourcing platforms
• Alternative H2 blockers and antacid products

Competition is usually commercial rather than litigation-driven. Retailers can switch suppliers without waiting for patent expiry if the replacement product meets FDA requirements and procurement specifications.

How strong is the patent estate for Rugby Heartburn Treatment?

The patent estate is likely weak for a conventional famotidine immediate-release tablet and potentially stronger for differentiated delivery systems.

Product architecture	Patent strength	Commercial defensibility
Conventional film-coated tablet	Low	Low to moderate
Chewable tablet with taste masking	Moderate	Moderate
Orally disintegrating tablet	Moderate	Moderate
Proprietary extended-release formulation	Moderate to high	Moderate to high
Liquid suspension	Low to moderate	Moderate through manufacturing know-how
Novel combination product	Moderate to high	Depends on regulatory and clinical support
Packaging and dispensing system	Low to moderate	Moderate if retailer-specific
Manufacturing process	Patent or trade-secret potential	High if scale-up is difficult

The strongest defensibility comes from a formulation that produces measurable advantages, such as faster disintegration, improved taste, longer stability in high humidity, lower tablet weight or reduced packaging requirements.

What commercial opportunities exist for Rugby Heartburn Treatment?

Premium private-label line

A premium line could use a chewable or orally disintegrating dosage form, improved flavor, smaller tablet size or unit-dose packaging. Retailers could position the product above basic generic famotidine while preserving a lower price than Pepcid.

Institutional and hospital supply

Hospitals and clinics value unit-dose packaging, barcode compatibility, stable supply and low total acquisition cost. A simple tablet with robust packaging may be more commercially valuable in this segment than a consumer-oriented formulation.

E-commerce multipacks

Famotidine is suitable for multipack and subscription sales because of its stable demand and long shelf life. High-barrier bottles or blister cards can support online distribution, where moisture exposure and package integrity must be controlled during shipping.

Dual-action products

A famotidine-antacid combination could provide both acid reduction and rapid neutralization. The commercial case is strong, but the formulation must address compatibility, dissolution, dose separation, label compliance and potential monograph limitations.

Traveler and portable packaging

Small blister packs, pocket-sized cartons and individually wrapped chewables can target travel and on-the-go use. The packaging change may create more commercial differentiation than a new excipient alone.

What generic launch risks exist?

Generic launch risk is low from an active-ingredient patent perspective but remains meaningful operationally.

The main risks are:

• FDA review or monograph noncompliance
• Failure of dissolution or content-uniformity testing
• Famotidine blend segregation
• Coating defects and tablet breakage
• Excipient supply interruption
• Packaging-related moisture degradation
• Retailer rejection due to appearance or consumer complaints
• Inadequate stability data for a new dosage form
• Product liability from labeling or dosing errors
• Price compression from multiple private-label suppliers

A conventional tablet can be launched with limited formulation novelty. A chewable, orally disintegrating or combination product requires more development work and carries greater regulatory and quality risk.

How does Rugby compare with Pepcid AC and other famotidine products?

Factor	Rugby Heartburn Treatment	Pepcid AC	Other store brands
Active ingredient	Famotidine	Famotidine	Usually famotidine
Brand premium	Low	High	Low
Formulation differentiation	Usually limited	Brand-dependent	Usually limited
Patent dependence	Low	Product-specific	Low
Retail price	Lowest or near-lowest	Highest	Low
Consumer trust	Retailer-dependent	Brand-driven	Retailer-dependent
Main advantage	Cost and availability	Recognition and marketing	Price competition
Best growth path	Dosage-form and packaging innovation	Brand extensions	Cost and supply efficiency

Rugby’s commercial advantage is procurement economics. Pepcid’s advantage is brand recognition. A Rugby line extension should therefore focus on convenience or format rather than attempting to replicate branded marketing spend.

Key Takeaways

• Rugby Heartburn Treatment is primarily a private-label famotidine opportunity.
• Standard immediate-release tablets have limited patent defensibility.
• The most important excipient objectives are content uniformity, rapid disintegration, acceptable hardness and low manufacturing cost.
• Crospovidone, croscarmellose sodium, microcrystalline cellulose, pregelatinized starch and controlled lubrication are likely formulation priorities.
• Chewable and orally disintegrating products offer the clearest premium opportunities.
• Taste masking, moisture protection and packaging compatibility are more important in differentiated formats.
• The product’s principal risks are regulatory compliance, supply continuity, quality performance and retailer economics rather than Paragraph IV litigation.
• A small, validated excipient platform across 10 mg and 20 mg strengths can reduce cost and improve manufacturing flexibility.
• Commercial protection is more likely to come from retailer contracts, quality performance, packaging and formulation know-how than from active-ingredient patents.

FAQs

Is famotidine in Rugby Heartburn Treatment the same active ingredient as Pepcid AC?

Yes. Rugby Heartburn Treatment products generally use famotidine, the same active ingredient used in Pepcid AC, although strength, inactive ingredients, labeling and dosage form can differ.

Can a new excipient combination receive a patent for famotidine tablets?

Potentially. A patent is more credible when the excipient system produces a demonstrated technical result, such as improved taste masking, stability, dissolution, moisture resistance or mechanical strength. A routine substitution of one standard excipient for another is less likely to provide strong protection.

Is an orally disintegrating famotidine product commercially attractive?

Yes. It can target consumers who have difficulty swallowing tablets or want water-free administration. The main development constraints are bitterness, friability, moisture sensitivity, packaging cost and regulatory pathway.

What packaging is best for private-label famotidine?

High-density polyethylene bottles with desiccant can support low-cost bulk distribution. Unit-dose or high-barrier blister packaging is better for portability, institutional use and moisture protection, but has higher packaging cost.

Does Rugby need a Paragraph IV strategy for standard famotidine tablets?

Usually not for a conventional OTC monograph-style product. Paragraph IV analysis becomes relevant only if the exact commercial product relies on an approved application with listed patents or claims a patented formulation, use or delivery system.

References

1. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

2. U.S. Food and Drug Administration. (n.d.). Electronic Orange Book patent and exclusivity information. https://www.fda.gov/drugs/drug-approvals-and-databases

3. U.S. Food and Drug Administration. (n.d.). DailyMed: Current labeling for prescription and nonprescription drug products. https://dailymed.nlm.nih.gov/dailymed/

4. U.S. Food and Drug Administration. (n.d.). 21 CFR Part 331: Antacid products for over-the-counter human use. Electronic Code of Federal Regulations. https://www.ecfr.gov/

5. U.S. Food and Drug Administration. (n.d.). Over-the-counter monograph system. https://www.fda.gov/drugs/over-counter-otc-nonprescription-medicines/otc-monograph-reform-including

6. U.S. Pharmacopeia. (2023). United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.